196 related articles for article (PubMed ID: 37947652)
21. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
[TBL] [Abstract][Full Text] [Related]
22. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT
Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263
[TBL] [Abstract][Full Text] [Related]
23. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
Kotani H; Tanabe H; Mizukami H; Amagaya S; Inoue M
Biol Pharm Bull; 2012; 35(1):1-9. PubMed ID: 22223330
[TBL] [Abstract][Full Text] [Related]
24. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
25. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
26. Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.
Pettersson F; Hanna N; Lagodich M; Dupéré-Richer D; Couture MC; Choi C; Miller WH
J Biol Chem; 2008 Aug; 283(32):21945-52. PubMed ID: 18544536
[TBL] [Abstract][Full Text] [Related]
27. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.
Sherman SI
Clin Lymphoma; 2003 Mar; 3(4):249-52. PubMed ID: 12672276
[TBL] [Abstract][Full Text] [Related]
28. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors.
Sanchez PV; Glantz ST; Scotland S; Kasner MT; Carroll M
Leukemia; 2014 Apr; 28(4):749-60. PubMed ID: 23823656
[TBL] [Abstract][Full Text] [Related]
29. A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.
Hanish BJ; Hackney Price JF; Kaneko I; Ma N; van der Vaart A; Wagner CE; Jurutka PW; Marshall PA
Steroids; 2018 Jul; 135():36-49. PubMed ID: 29704526
[TBL] [Abstract][Full Text] [Related]
30. Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer.
Leal AS; Hung PY; Chowdhury AS; Liby KT
Pharmacol Ther; 2023 Dec; 252():108561. PubMed ID: 37952906
[TBL] [Abstract][Full Text] [Related]
31. Evaluating Novel RXR Agonists That Induce ApoE and Tyrosine Hydroxylase in Cultured Human Glioblastoma Cells.
Mallick S; Marshall PA; Wagner CE; Heck MC; Sabir ZL; Sabir MS; Dussik CM; Grozic A; Kaneko I; Jurutka PW
ACS Chem Neurosci; 2021 Mar; 12(5):857-871. PubMed ID: 33570383
[TBL] [Abstract][Full Text] [Related]
32. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
Zhang D; Leal AS; Carapellucci S; Shahani PH; Bhogal JS; Ibrahim S; Raban S; Jurutka PW; Marshall PA; Sporn MB; Wagner CE; Liby KT
Cancer Prev Res (Phila); 2019 Apr; 12(4):211-224. PubMed ID: 30760500
[TBL] [Abstract][Full Text] [Related]
33. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro.
Kizaki M; Dawson MI; Heyman R; Elster E; Morosetti R; Pakkala S; Chen DL; Ueno H; Chao W; Morikawa M; Ikeda Y; Heber D; Pfahl M; Koeffler HP
Blood; 1996 Mar; 87(5):1977-84. PubMed ID: 8634447
[TBL] [Abstract][Full Text] [Related]
34. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
35. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
36. Bexarotene.
Lowe MN; Plosker GL
Am J Clin Dermatol; 2000; 1(4):245-50; discussion 251-2. PubMed ID: 11702369
[TBL] [Abstract][Full Text] [Related]
37. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status.
Fitzgerald P; Teng M; Chandraratna RA; Heyman RA; Allegretto EA
Cancer Res; 1997 Jul; 57(13):2642-50. PubMed ID: 9205071
[TBL] [Abstract][Full Text] [Related]
38. Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity.
Mounier A; Georgiev D; Nam KN; Fitz NF; Castranio EL; Wolfe CM; Cronican AA; Schug J; Lefterov I; Koldamova R
J Neurosci; 2015 Aug; 35(34):11862-76. PubMed ID: 26311769
[TBL] [Abstract][Full Text] [Related]
39. Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
Inoue M; Tanabe H; Nakashima K; Ishida Y; Kotani H
J Nat Prod; 2014 Jul; 77(7):1670-7. PubMed ID: 24959987
[TBL] [Abstract][Full Text] [Related]
40. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.
Li Y; Zhang Y; Hill J; Kim HT; Shen Q; Bissonnette RP; Lamph WW; Brown PH
Br J Cancer; 2008 Apr; 98(8):1380-8. PubMed ID: 18362934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
